和譽-B(02256.HK)2021年實現營收2270萬元 研發開支大幅提升至2.26億元
格隆匯3月18日丨和譽-B(02256.HK)公佈2021年度業績,集團收入從截至2020年12月31日止年度的零增加至截至2021年12月31日止年度的人民幣2270萬元,主要歸功於集團一項臨牀候選藥物產生的特許權使用費。
研發開支主要包括與探索性研究、臨牀前研究及臨牀研究有關的研發開支,以及試劑成本、僱員成本、許可費、以股份為基礎的付款及折舊。研發開支由截至2020年12月31日止年度的人民幣1.327億元增加人民幣9340萬元至截至2021年12月31日止年度的人民幣2.261億元,主要是由於研發相關職能不斷擴展、集團管線項目的推進以及特許權使用費減少的綜合影響。
於2021年12月31日,現金及銀行結餘為人民幣25.455億元(約合4.005億美元),較截至2020年12月31日止年度的人民幣6.178億元增加人民幣19.277億元,主要是由於2021年1月完成的D輪集資所收取的所得款項淨額及於2021年10月完成的首次公開發售的所得款項淨額。
於2021年7月,集團就ABSK021在罕見非腫瘤神經疾病領域適應症的研發及商業化與曙方(上海)醫藥科技有限公司訂立獨家許可協議。
集團已經建成由14個小分子腫瘤項目組成的管線,其中6個處於臨牀階段。利用集團的發現團隊及多維發現平台,集團不斷產生新的臨牀前候選藥物(”PCC“),以補充集團的臨牀管線。
值得一提的是,於2022年1月,集團與Eli Lilly and Company(”禮來“)訂立一項全球共同早期研發合作協議,以針對一項未公開靶點發現、開發新型分子並進行潛在商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.